This combination may benefit patients with Type 2 diabetes through substantial enhancement of the incretin axis. [50] A very low incidence of hypoglycemia occurs with sitagliptin, an incidence ...
Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback